Fundacion FERO

What Fundacion FERO does

Fundación FERO is a private Spanish non-profit foundation (fundación privada sin ánimo de lucro) established in 2001 that selects and finances translational oncology research projects in Spain. Its core "product" is a curated grant-making platform: the foundation identifies translational research projects with the highest probability of reaching cancer patients as treatments, and channels donated funds directly to those laboratories. The foundation operates a national network of four core research partners — VHIO Barcelona (Vall d'Hebron Institute of Oncology), INCLIVA Valencia, Hospital 12 de Octubre Madrid, and Clínic Barcelona — collectively delivering advanced molecular diagnostics, targeted therapies, and gynecological translational research to thousands of patients per year. Its flagship funding program is the V Beca FERO Dr. Baselga, awarded in 2026 to Gabriel Rabinovich for pancreatic cancer immunotherapy research in partnership with CaixaResearch Institute and Fundación la Caixa.

The foundation's revenue model is philanthropic rather than commercial. It raises funds through individual donations, a 'Hazte socio' recurring membership program, corporate contributions, in-memoriam giving, legacy/bequest programs, and an annual Gala FERO that alone is reported to raise approximately 1 million euros per event. In 2026 the foundation allocated approximately 1 million euros across seven active translational oncology research projects. Governance is provided by a Patronato (board) and a Scientific Committee that includes Dr. Josep Tabernero (Director of VHIO), lending scientific credibility to grant selection. FERO communicates impact through its website (ferocancer.org), earned media coverage in major Spanish outlets, events, and direct community engagement with the Spanish scientific research community.

The foundation is intentionally narrow in scope: 25 years of operating history have been devoted exclusively to Spanish translational oncology, differentiating it from general cancer charities by emphasizing clinical translation and measurable patient outcomes rather than basic discovery research. While it has no commercial product, no patents, no disclosed headcount, and no technology stack beyond its website, the organization has built a recognizable brand ("FERO Cáncer") and a curated research network that, in management's framing, allows donor capital to bypass generic funding pools and flow directly to laboratories with concrete clinical objectives.

Name

Fundacion FERO

Legal name

Fundación FERO

Website

https://fero.org

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

Fundación FERO is a Spanish non-profit foundation founded in 2001 that selects and finances translational oncology research projects at a national network of partner hospitals, raising funds through donations, membership, and an annual gala to channel capital directly to cancer laboratories.

Ownership category

akta.pro rank

Product category

Cancer Research Foundation

NAICS

Voluntary Health Organizations (813212)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industry

Grantmaking & Philanthropic Funds (Institutional Donors) (BPADAOAB)

Keywords

• Translational oncology research
• Cancer research funding
• Non-profit foundation
• Research grants
• Molecular diagnostics

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Services

Cost components

Others, Personnel, Operations, Marketing or Sales

Revenue model

1. Donations and Membership: FERO operates as a non-profit foundation that raises funds through donations from individuals, corporations, and events. The 'Hazte socio' (become a member) program suggests recurring membership contributions. Donations are directed specifically to laboratory research.

Distribution channels1 record

Marketing channels4 records

Core offering

Fundacion FERO is a private non-profit foundation that selects and finances translational oncology research in Spain. It raises funds through donations, memberships, and an annual gala, and channels approximately one million euros per year into a portfolio of cancer research projects executed by partner research centers (VHIO Barcelona, INCLIVA Valencia, Hospital 12 de Octubre Madrid, Clínic Barcelona, and CaixaResearch Institute), with measurable patient outcomes in molecular diagnostics, targeted therapies, and clinical trials.

Product overview

FERO Cáncer is a private non-profit foundation that selects and finances translational oncology research in Spain. Rather than offering commercial products, the foundation provides research funding programs including the V Beca FERO Dr. Baselga grant, various research project funding, and manages a network of research centers (VHIO Barcelona, INCLIVA Valencia, Hospital 12 de Octubre Madrid, Clínic Barcelona). The organization connects researchers with funding to accelerate the path from laboratory discovery to patient treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• V Beca FERO Dr. Baselga A prestigious translational cancer research grant named after Dr. Baselga, awarded to a researcher to develop new immunological strategies against cancer, with the 2026 edition directed at pancreatic cancer immunotherapy. For oncology researchers in Spain.
• Research Project Funding Direct project-based funding for translational oncology research with concrete clinical objectives and measurable patient outcomes. FERO has allocated approximately one million euros to seven active research projects. For Spanish oncology research institutions and investigators.
• FERO Cancer Research Network A network of funded research centers including VHIO Barcelona, INCLIVA Valencia, Hospital 12 de Octubre Madrid, and Clínic Barcelona, delivering advanced molecular diagnostics and targeted therapies to thousands of patients annually. For partner research institutions and the cancer patients they serve.
• Hazte Socio (Membership Program) A recurring membership donation program through which individual supporters contribute on an ongoing basis, with funds directed to FERO-funded translational oncology laboratories. For individual donors in Spain.

Quantifiable outcome

• 2,200+ patients per year receive advanced molecular diagnostics through VHIO Barcelona
• +4 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered flagship and core.

• CaixaResearch InstituteflagshipStrategic or Co-development Partner · 9 June 2026CaixaResearch Institute hosts the V Beca FERO Dr. Baselga awarded to Gabriel Rabinovich for pancreatic cancer immunotherapy research. This represents FERO's flagship research grant program in partnership with Fundacion la Caixa.
• VHIO Barcelona (Vall d'Hebron Institute of Oncology)coreStrategic or Co-development PartnerVHIO Barcelona serves as a primary research partner, conducting advanced molecular diagnostics that benefit 2,200 patients per year. FERO funding supports diagnostic molecular programs in solid tumors with direct patient impact.
• INCLIVA ValenciacoreStrategic or Co-development PartnerINCLIVA Valencia is a funded research partner focusing on targeted therapies for 279 patients annually. FERO investment enables continuation of therapeutic research lines that would otherwise be unsustained.
• Hospital 12 de Octubre MadridcoreStrategic or Co-development PartnerHospital 12 de Octubre conducts molecular diagnostics research with 40 patients currently enrolled in clinical trials. FERO funding supports this translational research with measurable clinical outcomes.
• Clínic BarcelonacoreStrategic or Co-development PartnerClínic Barcelona conducts gynecological translational research benefiting 300 patients per year. FERO enables maintenance of research lines focused on gynecological oncology with direct patient application.
• Fundacion la CaixaflagshipStrategic or Co-development PartnerCo-funding partner for the FERO Dr. Baselga fellowship program. The V Beca FERO Dr. Baselga was awarded in partnership with CaixaResearch Institute for immunotherapy research against pancreatic cancer.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fundacion FERO